Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and other neurodegenerative diseases. The company's lead product candidate, AMX0035, is a combination therapy designed to reduce the death of motor neurons. Amylyx was founded in 2013 by Joshua Cohen, Justin Klee, and Justin Yang, and is headquartered in Cambridge, Massachusetts.
Learn more about Amylyx Pharmaceutical